TickerFacts.

Biogen Inc. (BIIB): Total Liabilities

Annual figures by period end, from SEC filings.

$11.18B
As of 2025-12-31
$10.83B
As of 2026-03-31
+0.1%
3-year compound annual growth
-4.3%
5-year compound annual growth
+1.0%
10-year compound annual growth
$13.93B2008-12-31: $2.65B2009-12-31: $2.29B2010-12-31: $2.64B2011-12-31: $2.62B2012-12-31: $3.17B2013-12-31: $3.24B2014-12-31: $3.50B2015-12-31: $10.13B2016-12-31: $10.75B2017-12-31: $11.05B2018-12-31: $12.26B2019-12-31: $13.90B2020-12-31: $13.93B2021-12-31: $12.92B2022-12-31: $11.17B2023-12-31: $12.05B2024-12-31: $11.33B2025-12-31: $11.18B$11.18B
2008-12-31 Total Liabilities (USD) 2025-12-31
Period endedTotal LiabilitiesChange YoYSource filing
2025-12-31$11.18B-1.3%2026-02-06, Balance as of period end
2024-12-31$11.33B-5.9%2026-02-06, Balance as of period end
2023-12-31$12.05B+7.9%2025-02-12, Balance as of period end
2022-12-31$11.17B-13.6%2024-02-14, Balance as of period end
2021-12-31$12.92B-7.3%2023-02-15, Balance as of period end
2020-12-31$13.93B+0.3%2022-02-03, Balance as of period end
2019-12-31$13.90B+13.4%2021-02-03, Balance as of period end
2018-12-31$12.26B+10.9%2020-02-06, Balance as of period end
2017-12-31$11.05B+2.8%2019-02-06, Balance as of period end
2016-12-31$10.75B+6.1%2018-02-01, Balance as of period end
2015-12-31$10.13B+189.4%2017-02-02, Balance as of period end
2014-12-31$3.50B+8.0%2016-02-03, Balance as of period end
2013-12-31$3.24B+2.4%2015-02-04, Balance as of period end
2012-12-31$3.17B+20.7%2014-02-06, Balance as of period end
2011-12-31$2.62B-0.8%2013-02-05, Balance as of period end
2010-12-31$2.64B+15.4%2012-02-03, Balance as of period end
2009-12-31$2.29B-13.4%2011-02-04, Balance as of period end
2008-12-31$2.65Bn/a2010-02-09, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal LiabilitiesChange YoY
Biogen Inc. (BIIB)2025-12-31$11.18B-1.3%
Neurocrine Biosciences Inc (NBIX)2025-12-31$1.38B+22.1%
Exelixis, Inc. (EXEL)2026-01-02$683.10M-2.9%
Moderna, Inc. (MRNA)2025-12-31$3.69B+13.8%
Halozyme Therapeutics, Inc. (HALO)2025-12-31$2.48B+45.7%
Novavax Inc (NVAX)2025-12-31$1.30B-40.3%
BioCryst Pharmaceuticals Inc (BCRX)2025-12-31$633.31M-34.5%
Repligen Corp (RGEN)2025-12-31$843.57M-1.6%
ADMA Biologics, Inc. (ADMA)2025-12-31$146.92M+5.2%

Compare BIIB, NBIX, EXEL, MRNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗